CooperVision MiSight contact lens gets FDA approval to slow down myopia in children
Soft contact lens manufacturer CooperVision has secured approval for its MiSight contact lens from the US Food and Drug Administration (FDA) to slow the progression ... Read More
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu ... Read More
ProTom Radiance 330 proton therapy system bags FDA 510(k) Clearance
ProTom International has been given 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at the ... Read More
Vitruvias Therapeutics and Sinotherapeutics team up to launch bioequivalent Rythmol SR in US
Vitruvias Therapeutics, a US-based finished-dose generic drug manufacturer, has announced the US launch of a bioequivalent, FDA-approved version of the antiarrhythmic drug Rythmol SR, in ... Read More
Novartis secures FDA approval for Egaten as fascioliasis treatment
Novartis has achieved a significant milestone with the FDA's approval of Egaten (triclabendazole) for the treatment of fascioliasis in patients aged six years and older. ... Read More
Alexion Pharmaceuticals secures FDA priority review for SOLIRIS in neuromyelitis optica spectrum disorder
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor, SOLIRIS (eculizumab), as a treatment for neuromyelitis ... Read More
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical's ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV ... Read More
Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China
Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in ... Read More
Ablynx secures FDA approval for Cablivi to treat aTTP
In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted approval for Cablivi (caplacizumab-yhdp), a nanobody designed ... Read More
Pulmazole phase 2 clinical study gets FDA approval for Pulmazole in allergic bronchopulmonary aspergillosis
Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Pulmazole ... Read More